Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Search


Advanced search

Business Development

Corporations and Alliances

B·R·A·H·M·S Biomarkers focuses on research into biomarkers for in vitro diagnosis in medically relevant indications such as:
  • Sepsis
  • Markers for intensive care  
  • Markers for cardiovascular diseases
  • Lung diseases  
  • Prenatal screening/Down's Syndrome  
  • Tumour diseases

Do you have an innovative diagnostic biomarker and are looking for a partner for development, production and worldwide distribution?

Contact us

Technology Transferor and New Technologies

Our core technologies:
  • TRACE® technology (Time-Resolved Amplified Cryptate Emission). The laboratory analysis system KRYPTOR® with its TRACE® technology offers outstanding levels of accuracy.
  • Chemiluminescence
  • RIA
  • Point-of-care technology  

Do you have - if possible - quantitative and highly sensitive technology which is particularly suitable in the point-of-care field? Our Business Development Department evaluates and implements any potential co-operation and utilisation of your technologies with B·R·A·H·M·S Biomarkers.

Contact us

Potential BIOMARKERS for Diagnostics accompanying Therapy/THERANOSTICS

From their own basic research B·R·A·H·M·S Biomarkers have developed a number of biomarkers whose suitability for diagnostics, prognosis and therapy monitoring has been confirmed in extensive clinical trials.

These biomarkers - mainly from the areas of sepsis and cardiovascular diseases - have the potential to support an effective, patient-specific treatment choice.

You are looking for biomarkers which can be integrated into preclinical and clinical studies and thereby accelerate the development of your therapeutic innovations.

Contact us


Business Development

Tel: +49(0)3302.883.973
Fax: +49(0)3302.883-649